BioCentury | Oct 14, 2020
Management Tracks

Anderson joining Sofinnova Partners to bridge European biotechs to public markets

...1993. Sofinnova’s crossover fund has had two recent portfolio companies list on NASDAQ: renal company Calliditas Therapeutics AB...
...in June; and French NASH company Inventiva S.A. (Euronext:IVA; NASDAQ:IVA), which raised $107.7 million in July.Calliditas...
BioCentury | Aug 21, 2020
Management Tracks

IRRAS’s Wiklund has passed away

...the boards of more than a half a dozen life companies and chaired several, including Pharmalink...
BioCentury | Jun 6, 2020
Finance

Legend’s $424M NASDAQ offering pads 2020’s lead over prior years

...“Pliant is Latest to Climb on Public Debut” ). Also debuting on NASDAQ Friday was Calliditas Therapeutics AB...
...million ADSs at $19.50, and 924,000 shares at SEK89.7 ($9.80) in a concurrent private placement. Calliditas...
...for China Expansion” ). Elizabeth S. Eaton, Staff Writer Legend Biotechnology Co. Ltd. Pliant Therapeutics Inc. Applied Molecular Transport Inc Calliditas Therapeutics AB IPO...
BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

...already in progress of Nefecon, an enteric formulation of budesonide for IgA nephropathy. Its partner Calliditas Therapeutics AB...
BioCentury | Jun 3, 2020
Finance

Daily Chart: IPO queue grows to 20 life sciences companies

...see “CAR T Play Legend Looks to Lead Trio of Biotechs onto NASDAQ” ). Separately, Calliditas Therapeutics AB...
BioCentury | Jun 2, 2020
Finance

CAR T play Legend looks to lead trio of biotechs onto NASDAQ

...Leads BMS Deeper Into Synthetic Lethality” ). Both companies submitted their S-1s on Friday. Meanwhile, Calliditas Therapeutics AB...
...Integrin α(V)β(1) Jeff Cranmer, Executive Editor Legend Biotechnology Co. Ltd. Repare Therapeutics Inc. Lantern Pharma Inc. Pliant Therapeutics Inc. Forma Therapeutics Calliditas Therapeutics AB...
BioCentury | Apr 10, 2020
Management Tracks

Shakeup at Arix; plus Emergent, AlloVir, Asklepios Bio, Morphic, Gritstone and more

...and general counsel. He was general counsel at Opiant Pharmaceuticals Inc. (NASDAQ:OPNT). Renal disease company Calliditas Therapeutics AB...
...Minnesota Society of Clinical Oncology. Robin Sawka, BioCentury Staff Emergent BioSolutions Inc. Arix Bioscience plc AlloVir Asklepios BioPharmaceutical Inc. Gritstone Oncology Inc. Calliditas Therapeutics AB Gadeta...
BioCentury | Jan 10, 2020
Financial News

Jan. 9 Financial Quick Takes: Closes for two royalty funds; plus Apellis leads follow-on trio, Element, Omniome, Hinova, Emergex, Tscan, Calliditas

...Tracking Down Novel T Cell Targets” ). Calliditas seeking U.S. listing Swedish renal disease company Calliditas Therapeutics AB...
BioCentury | Aug 22, 2019
Financial News

Eyeing new endpoints, Versant-backed Chinook reels in $65M series A for kidney therapies

...York, N.Y.) gained rights in China and other Asian territories to Nefecon (PL-56, Nefigan) from Calliditas Therapeutics AB...
BioCentury | Jul 3, 2019
Financial News

July 3 Financial Quick Takes: Mega-round for China’s Lepu; plus Citryll, Jibeier and Calliditas

...medicines. Calliditas raises $22.6M A year after going public on NASDAQ Stockholm, renal disease company Calliditas Therapeutics AB...
...BVF Partners L.P. (see "Calliditas Raises Over $70M in Swedish IPO" ). Elizabeth S. Eaton, Staff Writer Calliditas Therapeutics AB Citryll...
Items per page:
1 - 10 of 41
BioCentury | Oct 14, 2020
Management Tracks

Anderson joining Sofinnova Partners to bridge European biotechs to public markets

...1993. Sofinnova’s crossover fund has had two recent portfolio companies list on NASDAQ: renal company Calliditas Therapeutics AB...
...in June; and French NASH company Inventiva S.A. (Euronext:IVA; NASDAQ:IVA), which raised $107.7 million in July.Calliditas...
BioCentury | Aug 21, 2020
Management Tracks

IRRAS’s Wiklund has passed away

...the boards of more than a half a dozen life companies and chaired several, including Pharmalink...
BioCentury | Jun 6, 2020
Finance

Legend’s $424M NASDAQ offering pads 2020’s lead over prior years

...“Pliant is Latest to Climb on Public Debut” ). Also debuting on NASDAQ Friday was Calliditas Therapeutics AB...
...million ADSs at $19.50, and 924,000 shares at SEK89.7 ($9.80) in a concurrent private placement. Calliditas...
...for China Expansion” ). Elizabeth S. Eaton, Staff Writer Legend Biotechnology Co. Ltd. Pliant Therapeutics Inc. Applied Molecular Transport Inc Calliditas Therapeutics AB IPO...
BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

...already in progress of Nefecon, an enteric formulation of budesonide for IgA nephropathy. Its partner Calliditas Therapeutics AB...
BioCentury | Jun 3, 2020
Finance

Daily Chart: IPO queue grows to 20 life sciences companies

...see “CAR T Play Legend Looks to Lead Trio of Biotechs onto NASDAQ” ). Separately, Calliditas Therapeutics AB...
BioCentury | Jun 2, 2020
Finance

CAR T play Legend looks to lead trio of biotechs onto NASDAQ

...Leads BMS Deeper Into Synthetic Lethality” ). Both companies submitted their S-1s on Friday. Meanwhile, Calliditas Therapeutics AB...
...Integrin α(V)β(1) Jeff Cranmer, Executive Editor Legend Biotechnology Co. Ltd. Repare Therapeutics Inc. Lantern Pharma Inc. Pliant Therapeutics Inc. Forma Therapeutics Calliditas Therapeutics AB...
BioCentury | Apr 10, 2020
Management Tracks

Shakeup at Arix; plus Emergent, AlloVir, Asklepios Bio, Morphic, Gritstone and more

...and general counsel. He was general counsel at Opiant Pharmaceuticals Inc. (NASDAQ:OPNT). Renal disease company Calliditas Therapeutics AB...
...Minnesota Society of Clinical Oncology. Robin Sawka, BioCentury Staff Emergent BioSolutions Inc. Arix Bioscience plc AlloVir Asklepios BioPharmaceutical Inc. Gritstone Oncology Inc. Calliditas Therapeutics AB Gadeta...
BioCentury | Jan 10, 2020
Financial News

Jan. 9 Financial Quick Takes: Closes for two royalty funds; plus Apellis leads follow-on trio, Element, Omniome, Hinova, Emergex, Tscan, Calliditas

...Tracking Down Novel T Cell Targets” ). Calliditas seeking U.S. listing Swedish renal disease company Calliditas Therapeutics AB...
BioCentury | Aug 22, 2019
Financial News

Eyeing new endpoints, Versant-backed Chinook reels in $65M series A for kidney therapies

...York, N.Y.) gained rights in China and other Asian territories to Nefecon (PL-56, Nefigan) from Calliditas Therapeutics AB...
BioCentury | Jul 3, 2019
Financial News

July 3 Financial Quick Takes: Mega-round for China’s Lepu; plus Citryll, Jibeier and Calliditas

...medicines. Calliditas raises $22.6M A year after going public on NASDAQ Stockholm, renal disease company Calliditas Therapeutics AB...
...BVF Partners L.P. (see "Calliditas Raises Over $70M in Swedish IPO" ). Elizabeth S. Eaton, Staff Writer Calliditas Therapeutics AB Citryll...
Items per page:
1 - 10 of 41